Male Reproductive

Peyronie disease: diagnosis and management

Clinical Overview and When to Suspect Peyronie Disease

— Prevalence ~3–9% of adult men; underreported due to embarrassment

— Peak onset ages 50–60; rising incidence with aging population and PDE5i use

— Strong association with Dupuytren contracture (~15–20%), Ledderhose disease, and plantar fascia fibrosis

— Acute/active phase (≤12 months): pain with erection, evolving curvature, plaque still soft/forming

— Chronic/stable phase (>12 months, ≥3 months stable): pain resolves, curvature/plaque fixed, calcification possible

— Middle-aged man reports new penile curvature, "bend," hourglass deformity, or shortening

— Painful erections without trauma history

— New-onset ED with palpable dorsal penile nodule

— Difficulty with vaginal penetration despite adequate erection

Definition: Acquired fibrotic disorder of the tunica albuginea of the penis, producing a palpable plaque, penile curvature, pain with erection, and often erectile dysfunction (ED). Considered a localized connective tissue/wound-healing disorder.

Epidemiology (Step 3 relevance):

Pathophysiology: Repetitive microtrauma during intercourse → aberrant TGF-β–driven fibrosis → collagen plaque in tunica albuginea → asymmetric tethering during erection → curvature.

Two phases (must distinguish on exam):

When to suspect in primary care:

Risk factors: Diabetes, hypertension, hyperlipidemia, low testosterone, smoking, pelvic/perineal trauma, prior radical prostatectomy, family history, Dupuytren contracture.

Board pearl: Always screen for Dupuytren contracture (palmar nodules, ring/small finger flexion) in a man presenting with penile curvature — the association is classic on Step 3 stems.

Step 3 management: This is largely an outpatient family medicine / urology comanaged condition; the family physician's role is recognition, reassurance, screening for cardiovascular risk and ED comorbidity, and timely urology referral before the stable phase locks in deformity.

Presentation Patterns and Key History

— Palpable penile plaque (dorsal >>> lateral/ventral)

— Penile curvature with erection (most often dorsal)

— Pain with erection (acute phase) or painless deformity (chronic phase)

— Penile shortening (very distressing, often the chief complaint)

— Hourglass or "hinge" deformity → buckling and inability to penetrate

— New or worsening erectile dysfunction (in ~50%; may be venous leak from plaque)

— Reduced sexual satisfaction for patient and/or partner; relationship distress

— Onset and duration: <12 months suggests active phase (treatment window for intralesional therapy)

— Stability: curvature unchanged for ≥3 months and pain resolved = stable phase

— Direction and degree of curvature; ability to have intercourse

— Sexual function: rigidity, libido, ejaculation, partner availability

— Recent pelvic trauma, vigorous intercourse, or instrumentation

— Prior radical prostatectomy (independent risk factor)

— Comorbidities: DM, HTN, dyslipidemia, low T symptoms, tobacco use

— Family history of Peyronie or Dupuytren; personal Dupuytren/Ledderhose

— Medications: beta-blockers historically implicated (weak evidence)

— Depression, anxiety, and relationship strain occur in ~50%

— Use PHQ-9; consider partner involvement in counseling

— PDQ (Peyronie Disease Questionnaire) quantifies bother and psychological impact

— IIEF-5/SHIM for ED severity

Classic triad on presentation:

Additional presenting complaints:

Key history elements to obtain:

Psychosocial screening (Step 3 essential):

Validated tools:

Key distinction: Distinguish congenital penile curvature (lifelong, no plaque, presents in adolescence/young adulthood, ventral curvature common) from acquired Peyronie disease (adult onset, palpable plaque, pain in active phase). Stem language about "noticed bending since adolescence with no nodule" → congenital, not Peyronie.

Board pearl: Document photographs of erect penis (home self-photos from multiple angles) — standard, AUA-endorsed, and frequently the right next step on a vignette before invasive imaging.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Assess for Dupuytren contracture (palmar fascia nodules, 4th/5th digit flexion)

— Plantar fascia for Ledderhose disease

— Signs of hypogonadism (gynecomastia, decreased body hair, testicular size)

— Stretch the penis gently to flatten tunica → palpate dorsal, lateral, and ventral shafts

— Plaque is typically a firm, well-demarcated nodule or ridge, most often dorsal midline, distal to the base

— Note plaque location, size (cm), number, and tenderness (tender = active phase)

— Calcified plaques feel rock-hard, sometimes gritty

— Measure stretched penile length (proxy for erect length) — baseline before therapy

— Cannot be reliably assessed on flaccid exam

— Use patient-supplied photographs of erect penis (AP and lateral) OR

— In-office intracavernosal injection (alprostadil/trimix) to induce erection and measure with goniometer — gold standard for curvature degree

— Direction: dorsal (most common), lateral, ventral, complex/biplanar

— Degree: mild <30°, moderate 30–60°, severe >60°

— Hinge effect or hourglass narrowing — functionally disabling even at low angles

— Penile duplex Doppler ultrasound after intracavernosal vasoactive injection

— Assesses peak systolic velocity (PSV <25 cm/s = arterial insufficiency) and end-diastolic velocity (EDV >5 cm/s = venous leak, common with Peyronie plaques)

— Also localizes and sizes plaque, detects calcification

General exam:

Focused genital exam (flaccid state):

Curvature assessment:

Curvature characterization:

Hemodynamic / erectile assessment when ED coexists:

CCS pearl: On a CCS-style case, after history and focused exam, order "penile duplex ultrasound with intracavernosal injection" when you need objective curvature degree, plaque characterization, AND hemodynamic data in a single study — efficient sequencing before urology referral.

Board pearl: Tenderness on palpation of the plaque is a clinical marker of active disease; absence of tenderness for ≥3 months supports stable phase suitable for definitive surgical planning.

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Fasting glucose / HbA1c — diabetes screening; DM is a major risk factor and predicts worse ED

— Lipid panel — vasculogenic ED screen

— Morning total testosterone (×2 if low) — low T worsens ED and may affect treatment response; check LH, prolactin if low

— CBC, CMP — only if planning intralesional therapy or surgery

— Coagulation studies if on anticoagulation and considering injection therapy

— Penile duplex ultrasound with intracavernosal vasoactive injection is the single most useful test

— Confirms and characterizes plaque (size, location, calcification)

— Quantifies curvature objectively

— Assesses cavernosal arterial flow and venous competence

— Office-based, well tolerated, no ionizing radiation

— Not routine

— MRI with gadolinium occasionally reserved for complex/multiplanar plaques or preoperative planning; can detect plaque inflammation

— CT has no routine role

— Not directly for Peyronie, BUT erectile dysfunction is a sentinel marker of cardiovascular disease

— A man with new ED and Peyronie deserves global CV risk assessment: BP, lipids, ASCVD risk score, lifestyle counseling — classic Step 3 preventive medicine integration

— Do not biopsy the plaque — risk of worsening fibrosis, no clinical benefit

— Do not order tumor markers; plaques are benign fibrotic lesions, not neoplastic

Peyronie disease is fundamentally a clinical diagnosis — history + palpable plaque + curvature. Workup targets comorbidities, severity, and surgical planning.

Initial labs (selective, not universal):

No specific biomarker exists for Peyronie disease; no role for inflammatory markers (ESR/CRP) routinely.

Imaging — first-line:

Plain radiography / MRI:

ECG / cardiac workup:

What NOT to do:

Board pearl: New-onset ED in a middle-aged man = "canary in the coal mine" for cardiovascular disease — order lipid panel, A1c, BP, and calculate 10-year ASCVD risk. This integration is heavily tested on Step 3.

Step 3 management: In the outpatient setting, confirm diagnosis clinically, screen metabolic/CV risk, obtain home erect-state photographs, and refer to urology for duplex ultrasound and treatment planning within the active-phase window.

Diagnostic Workup — Advanced or Confirmatory Studies

— Performed after intracavernosal injection of alprostadil or trimix

— Measures peak systolic velocity (PSV) and end-diastolic velocity (EDV) in cavernosal arteries at 5, 10, 15, 20 min

— Normal: PSV ≥30 cm/s, EDV <5 cm/s, resistive index >0.8

— Arterial insufficiency: PSV <25 cm/s

— Venous leak (veno-occlusive dysfunction): EDV >5 cm/s — common in Peyronie because the plaque tethers tunica and disrupts veno-occlusion

— Provides curvature measurement using goniometer at maximal rigidity

— Reserved for complex deformities, suspected septal involvement, or preoperative planning when ultrasound is equivocal

— Gadolinium enhancement may indicate active inflammation (correlates with active phase)

— Not first-line due to cost

— Largely historical; rarely needed today

— Considered when venous leak is suspected but duplex is inconclusive, particularly before complex reconstructive surgery

— PDQ (Peyronie Disease Questionnaire): 15-item, three domains — psychological/physical symptoms, penile pain, symptom bother. Tracks treatment response

— IIEF/SHIM: quantifies ED

— EDITS for treatment satisfaction

— Standardized erect-state photographs from multiple angles, at home, before and after therapy

— Now an AUA-endorsed objective measure

— Not routinely indicated

— Consider only if syndromic features (e.g., diffuse fibromatosis, family clustering)

Penile duplex Doppler ultrasound (PDDU) — gold standard adjunct:

MRI of the penis:

Dynamic infusion cavernosometry/cavernosography:

Validated patient-reported outcome measures (PROMs):

Photographic documentation:

Genetic / connective tissue workup:

Key distinction: Duplex ultrasound characterizes plaque AND hemodynamics in one study and is first-line advanced imaging; MRI is reserved for surgical planning of complex/multiplanar curvature or when ultrasound is non-diagnostic. Don't pick MRI as the initial advanced study on a vignette.

Board pearl: A venous leak pattern (EDV >5 cm/s) on duplex predicts poor response to PDE5 inhibitors alone and suggests the patient may ultimately need a penile prosthesis if ED is significant — a high-yield correlation.

Risk Stratification or First-Line Management Logic

— Goals: stabilize disease, reduce pain, prevent progression

— Avoid surgery — deformity not yet fixed

— Candidates for intralesional therapy and oral/mechanical adjuncts

— Goals: correct deformity, restore function

— Candidates for surgical correction if functionally disabling (curvature >30°, hinge effect, inability to have intercourse)

— Mild (<30°, no functional impairment): reassurance, observation, treat coexisting ED, lifestyle/CV risk modification; ~13% spontaneously improve, most stabilize

— Moderate (30–60°, some functional limitation): intralesional collagenase (Xiaflex) if stable; consider traction therapy; surgery if stable and disabling

— Severe (>60°, hinge effect, inability to penetrate, severe ED): surgical correction (plication, plaque incision/grafting, or penile prosthesis if concurrent severe ED)

— Discuss natural history: pain usually resolves; curvature rarely resolves spontaneously; ~40% worsen without treatment

— Set realistic expectations: no therapy fully "cures" Peyronie; goal is functional, not cosmetic, perfection

— Involve partner when appropriate

— Treat ED with PDE5 inhibitors early; daily low-dose tadalafil may also have antifibrotic effects (modest evidence)

— If severe ED + severe curvature → penile prosthesis with simultaneous straightening is often the single best operation

Phase determines therapy — the single most important treatment decision in Peyronie disease.

Active (acute) phase — ≤12 months from onset, pain present, deformity evolving:

Stable (chronic) phase — >12 months, ≥3 months without change, no pain:

Severity stratification for treatment selection:

AUA guideline-aligned shared decision-making:

Concurrent ED management is integral:

Step 3 management: Triage in clinic by phase + severity + ED status: active mild → reassurance + ED treatment + CV risk reduction; active moderate → urology referral for intralesional collagenase; stable severe with good erections → plication or grafting; stable severe with poor erections → prosthesis.

Board pearl: Do not operate during the active phase — deformity is still evolving and recurrence/progression is likely. Wait until ≥3 months of stability and ≥12 months from onset.

Pharmacotherapy — First-Line Drug Regimen

— Vitamin E (400 IU/day): no proven benefit in RCTs; cheap and safe; often offered for psychological benefit/placebo

— Colchicine, tamoxifen, potassium para-aminobenzoate (Potaba), pentoxifylline: evidence weak/conflicting; AUA states should not be offered as primary therapy

— Pentoxifylline (400 mg TID) has theoretical antifibrotic effect; small studies suggest plaque stabilization — sometimes used off-label in active phase

— L-arginine and acetyl-L-carnitine: no convincing benefit

— Treat coexisting ED

— Daily low-dose tadalafil 2.5–5 mg may have antifibrotic effects on septal plaques (limited evidence)

— Improves rigidity, which can functionally compensate for mild curvature

— Collagenase Clostridium histolyticum (CCH, Xiaflex) — only FDA-approved drug for Peyronie disease

— Indication: stable phase, palpable plaque, curvature 30°–90°, no ventral curvature, no severe calcification

— Regimen: Up to 4 treatment cycles, each consisting of 2 injections of 0.58 mg given 1–3 days apart, followed by penile modeling (stretching) by the urologist and home modeling/traction by the patient; cycles separated by ~6 weeks

— Efficacy: ~34% mean reduction in curvature, improved PDQ bother

— Adverse effects: ecchymosis, swelling, pain; corporal rupture (~0.5%) and penile hematoma — must counsel to avoid sexual activity for 4 weeks post-injection

— Contraindications: ventral plaques (urethral proximity), heavy calcification, active phase

— Intralesional verapamil (10 mg per session, biweekly ×12): off-label, lower cost, modest benefit; reasonable when CCH unavailable or contraindicated

— Intralesional interferon α-2b: option per AUA; less commonly used due to flu-like side effects

— Intralesional steroids: NOT recommended — no benefit, risks tissue atrophy

Oral therapies — AUA: limited evidence, generally not recommended as monotherapy, but commonly used:

PDE5 inhibitors (sildenafil, tadalafil):

Intralesional injection therapy — the cornerstone of medical management:

Topical therapies: Topical verapamil and H-100 lack convincing evidence; AUA recommends against topical verapamil.

Key distinction: CCH (Xiaflex) is for the stable phase, NOT acute — a frequent distractor. Acute-phase patients should be observed, treated for pain/ED, and offered traction therapy while awaiting stabilization.

Board pearl: Vitamin E is the classic "wrong answer that sounds right" — it is widely prescribed but has no evidence of efficacy; AUA does not recommend it as effective therapy.

Procedures / Revascularization / Invasive Management

— Indication: curvature <60°, adequate erectile function, adequate penile length, no hourglass/hinge

— Technique: plicate the tunica on the convex (longer) side to straighten

— Pros: technically simpler, low complication rate, preserves erectile function

— Cons: penile shortening (1–1.5 cm typical) — must counsel preoperatively

— Success rate ~85–90% straightening

— Indication: curvature >60°, hourglass deformity, complex/biplanar curvature, short penis; adequate erectile function required

— Technique: incise the concave (shorter) side through the plaque; defect covered with graft (bovine pericardium, porcine SIS, autologous vein, dermis)

— Pros: preserves/restores length, corrects severe deformity

— Cons: higher risk of postoperative ED (~15–25%) due to neurovascular dissection; longer recovery

— Avoid in patients with borderline erections

— Indication: Peyronie + significant ED unresponsive to PDE5i, especially with severe curvature or hourglass

— Often combined with manual modeling (Wilson maneuver), plication, or grafting at the same operation

— Single procedure addresses both problems; highest patient and partner satisfaction in this subgroup

— Penile traction therapy (PTT) — daily wear of a traction device (e.g., RestoreX) 30–90 min/day; modest curvature reduction (~10–15°) and length gain; useful in active phase, adjunct to CCH, and post-surgery

— Vacuum erection devices: limited evidence; sometimes used for length preservation

— Shockwave therapy (Li-ESWT): may reduce pain in active phase; no significant curvature improvement — AUA: do not offer for curvature reduction

Surgery is definitive treatment for stable-phase Peyronie disease with functionally disabling deformity. Prerequisites: ≥12 months from onset, ≥3 months of stability, patient understands realistic outcomes.

Three principal surgical approaches — selection by curvature severity and erectile function:

1. Tunical plication (Nesbit, Yachia, 16-dot plication):

2. Plaque incision/excision with grafting:

3. Penile prosthesis (inflatable):

Adjunctive nonsurgical procedures:

Step 3 management: Procedural choice algorithm — good erections + <60° curve → plication; good erections + >60° or complex curve → incision/grafting; poor erections + Peyronie → inflatable penile prosthesis with modeling.

Board pearl: Plication shortens; grafting preserves length but risks ED. This trade-off is the single most testable surgical decision in Peyronie disease.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of comorbid ED, diabetes, vascular disease, hypogonadism

— Greater baseline rates of CV disease — careful preoperative assessment if considering surgery

— Often have less interest in aggressive surgery; goals-of-care conversation essential — some prioritize pain relief and partner intimacy over full straightening

— Penile prosthesis is frequently the most efficient single intervention in older men with combined Peyronie + ED — high satisfaction, durable

— All Peyronie patients with ED need ASCVD risk stratification

— Before initiating PDE5 inhibitors: confirm no nitrate use, assess exercise tolerance (≥3–5 METs for sexual activity), recent MI/unstable angina

— Stable CAD on optimal therapy: PDE5i generally safe

— Sildenafil: start at 25 mg if CrCl <30 mL/min

— Tadalafil: avoid daily dosing if CrCl <30; use 5–10 mg PRN with caution

— Vardenafil: start at 5 mg in severe renal impairment

— Collagenase (CCH): no renal dose adjustment; systemic absorption negligible

— Sildenafil/tadalafil/vardenafil: start at low doses (25 mg sildenafil, 5 mg tadalafil) in Child-Pugh A–B; avoid in Child-Pugh C

— CCH: no specific hepatic adjustment, but caution with coexistent coagulopathy

— Patients on warfarin, DOACs, or dual antiplatelet therapy have increased risk of penile hematoma with intralesional injection or surgery

— AUA recommends caution; many urologists hold anticoagulation per standard perioperative protocols before CCH or surgical correction

— Aspirin monotherapy is generally continued

— Up to 25% of Peyronie patients have low testosterone; correlates with poorer ED outcomes

— Replace testosterone if confirmed deficient (two morning low T levels + symptoms) — screen prostate (DRE, PSA) and hematocrit before initiating

Elderly men (>65) — by far the predominant Peyronie demographic:

Cardiovascular risk integration:

Renal impairment:

Hepatic impairment:

Anticoagulation considerations:

Hypogonadism:

Key distinction: PDE5 inhibitors are absolutely contraindicated with any nitrate (including nitroglycerin SL, isosorbide, recreational "poppers") — hypotensive crisis. This is a perennial Step 3 stem in older men with CAD + ED.

Board pearl: In an elderly man with Peyronie disease + severe ED + comorbid disease, a single inflatable penile prosthesis surgery is often more efficient and satisfying than staged medical therapy — recognize this on CCS-style management cases.

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— Peyronie disease itself is exceedingly rare in pediatrics

— A young man (teens to 20s) with curvature almost always has congenital penile curvature, not Peyronie

— Lifelong history of curvature

— No palpable plaque

— Ventral curvature most common (sometimes associated with hypospadias)

— Surgical correction (plication) deferred until skeletal/genital maturity and only if functionally limiting

— Always rule out chordee (fibrous band causing ventral curvature, often associated with hypospadias)

— Tends to be more aggressive course, more pain, more rapid progression

— Active phase may be longer; refer early to urology

— Greater psychological burden — screen aggressively for depression, anxiety, relationship dysfunction

— Fertility considerations: Peyronie doesn't impair fertility directly, but inability to have penetrative intercourse may — discuss assisted reproduction options if relevant

— Radical prostatectomy is an independent risk factor; 15–16% develop Peyronie within 1–2 years post-op

— Likely mechanism: cavernosal nerve injury, ischemic fibrosis, and disuse atrophy

— Penile rehabilitation (early PDE5i, vacuum device, possibly traction) post-prostatectomy may reduce incidence — increasingly standard of care

— Higher prevalence of both Peyronie and ED

— More likely to have severe ED and to require prosthesis ultimately

— Optimize glycemic control as part of management

— Partner dyspareunia is common with significant curvature

— Involve partner in counseling and shared decision-making when appropriate

— Address relationship dysfunction with referral to sex therapy/couples counseling

Pediatrics / adolescents:

Young adults with acquired Peyronie disease:

Post-prostatectomy patients:

Diabetic men:

Partner considerations (not a "population" but Step 3 relevant):

Pregnancy: Not applicable to the patient; partner's fertility unaffected by Peyronie per se.

Key distinction: Congenital penile curvature = lifelong, ventral, no plaque, no pain, often with hypospadias; Peyronie disease = acquired in adulthood, dorsal, palpable plaque, painful in active phase. Age and plaque are the two highest-yield discriminators.

Board pearl: A man 1 year out from radical prostatectomy presenting with new penile curvature and a dorsal plaque has Peyronie disease — a tested complication of prostatectomy, not a coincidental finding.

Complications and Adverse Outcomes

— Erectile dysfunction (~50% of patients): multifactorial — venous leak from plaque-disrupted veno-occlusion, anxiety, vascular comorbidity

— Penile shortening: from fibrotic tethering and/or surgical plication; major source of distress

— Inability to have penetrative intercourse: hinge/hourglass deformity, severe curvature

— Chronic pain: usually limited to active phase; persistent pain beyond 18 months is unusual

— Psychological morbidity: depression in ~48%, anxiety, relationship dysfunction, body image distress, decreased self-esteem

— Penile ecchymosis (very common, ~80%) and edema

— Local pain

— Corporal rupture (~0.5%): presents as sudden detumescence, audible pop, severe swelling — urologic emergency, requires surgical repair

— Penile hematoma (~3–4%): typically managed conservatively with compression

— Counseling point: abstain from intercourse and masturbation for 4 weeks after each injection cycle

— Penile shortening (1–1.5 cm, occasionally more)

— Recurrence of curvature (5–15%)

— Palpable suture knots

— Penile sensory changes

— Rarely ED

— ED in 15–25% (cavernosal nerve injury, venous leak through graft)

— Graft bulging, recurrence

— Sensory changes (transient or permanent)

— Hematoma, infection

— Length preservation usually achieved

— Infection (1–3%; higher in DM, revisions)

— Mechanical failure (~5% at 5 years)

— Erosion, malposition

— Need for revision surgery

— Once placed, eliminates natural erections permanently

Disease-related complications:

Treatment-related complications:

Intralesional collagenase (CCH/Xiaflex):

Surgical complications — plication:

Surgical complications — plaque incision/grafting:

Penile prosthesis complications:

Step 3 management: Sudden detumescence with severe pain and swelling after CCH injection = suspect corporal rupture → urgent urology evaluation, MRI or surgical exploration, repair of tunica defect. Recognize this complication immediately on a CCS-style stem.

Board pearl: Depression screening (PHQ-9) is a core component of Peyronie management — psychological morbidity is as functionally limiting as the curvature itself, and untreated depression undermines treatment adherence and outcomes.

When to Escalate Care — Urology Consult or Inpatient Triage

— Suspected corporal rupture after CCH injection or trauma: sudden detumescence, audible pop, severe swelling, ecchymosis → urgent surgical evaluation

— Priapism following intracavernosal vasoactive injection (alprostadil/trimix) lasting >4 hours → urology emergency, aspiration and phenylephrine irrigation

— Expanding penile hematoma with hemodynamic concern (rare) → ED evaluation

— Inability to void with associated penile pathology (very uncommon) → urology

— Confirm diagnosis, perform duplex ultrasound, document curvature

— Discuss phase-specific treatment options

— Initiate intralesional therapy if indicated

— Plan surgical correction in stable phase if disabling

— PHQ-9 ≥10 (moderate depression)

— Suicidal ideation — immediate evaluation

— Severe relationship dysfunction → couples or sex therapy

— Confirmed hypogonadism with complex presentation (e.g., low T + high prolactin, or low T + low LH suggesting central cause)

— Otherwise, testosterone replacement can be initiated by family medicine

— ED + Peyronie in a man with known CAD, prior MI, or abnormal stress test before initiating PDE5 inhibitors or planning surgery

— Exercise tolerance <4 METs requires CV clearance before sexual activity counseling

— Postoperative complications (infection, hematoma requiring drainage)

— Penile prosthesis infection requiring IV antibiotics and possible explantation

— Corporal rupture requiring operative repair

Peyronie disease is overwhelmingly an outpatient, urology-comanaged condition — true inpatient admission is rare. Escalation typically means specialty referral or urgent same-day urology evaluation.

Urgent urology referral (same-day or ED) — true emergencies/urgencies:

Routine urology referral — all newly diagnosed Peyronie patients:

Mental health referral indications:

Endocrinology referral:

Cardiology referral:

Inpatient admission — rare scenarios:

CCS pearl: On a CCS case of a man with sudden penile detumescence, severe pain, and swelling after intercourse or after CCH injection, order: urgent urology consult, IV access, NPO, type and screen, pain control, and either bedside ultrasound or MRI to characterize tunical defect — then OR for surgical repair. Do not delay with extensive imaging.

Step 3 management: Family physician's role is early recognition, comorbidity workup, photographic documentation, and timely referral within the active-phase therapeutic window (ideally <12 months from onset for intralesional candidacy planning).

Key Differentials — Same-Category Causes (Penile Pathology)

— Lifelong, noticed at puberty or with first erections

— No palpable plaque

— Usually ventral curvature; may be associated with hypospadias or chordee

— No pain

— Treatment: plication if functionally disabling, after maturity

— Ventral bowing from fibrous tissue along urethra, often congenital

— Frequently associated with hypospadias

— Distinguished by absence of tunical plaque and presence of urethral abnormality

— Acute traumatic rupture of tunica albuginea during intercourse

— Audible pop, immediate detumescence, "eggplant deformity," severe pain

— Surgical emergency — repair within 24 hours

— Can leave residual plaque/curvature that mimics Peyronie

— Ulcerated or fungating lesion on glans/foreskin, not a deep tunical nodule

— Risk factors: HPV, phimosis, lack of circumcision, smoking

— Biopsy mandatory — unlike Peyronie plaques, suspicious lesions must be sampled

— Key distinction: superficial/mucosal vs. deep/tunical

— Thrombosed superficial dorsal lymphatic or vein

— Cord-like, superficial, often appears after vigorous intercourse

— Self-limited over weeks; not within tunica

— Differentiated from Peyronie by superficial location and tubular (not nodular) feel

— Rare; mass effect, systemic symptoms; biopsy diagnostic

— Mobile subcutaneous mass, not within tunica

— Benign, excisable

— History of prolonged priapism leads to cavernosal fibrosis

— Diffuse stiffness rather than discrete dorsal plaque

— Often associated with severe ED

— Indistinguishable from idiopathic Peyronie — same pathophysiology, identified trauma

Congenital penile curvature:

Chordee:

Penile fracture:

Penile cancer (SCC):

Penile sclerosing lymphangitis (Mondor disease of the penis):

Penile lymphoma / sarcoma:

Epidermoid cyst of the penile shaft:

Post-priapism fibrosis:

Post-traumatic fibrosis (subclinical Peyronie):

Key distinction: Mondor disease is a superficial, cord-like thrombosed dorsal vessel that resolves spontaneously; Peyronie is a deep tunical plaque causing erectile curvature. Don't confuse the two on a vignette — palpation depth and chronicity are the discriminators.

Board pearl: Any ulcerated or exophytic lesion on the glans or penile skin warrants biopsy to exclude SCC — Peyronie plaques are never ulcerated and never involve the skin surface; skin involvement should redirect your differential.

Key Differentials — Other-Category Causes (Systemic / Functional)

— Vasculogenic ED (most common, atherosclerosis, DM)

— Neurogenic ED (post-prostatectomy, spinal cord injury, MS, diabetic neuropathy)

— Endocrine ED (hypogonadism, hyperprolactinemia, thyroid disease)

— Psychogenic ED (situational, performance anxiety; preserved nocturnal erections)

— Medication-induced (SSRIs, beta-blockers, thiazides, finasteride, opioids)

— These present with erectile failure without curvature or plaque — different management algorithm

— Dupuytren contracture (palmar fascia) — 15–20% comorbidity

— Ledderhose disease (plantar fascia)

— Knuckle pads (Garrod nodes)

— Collectively suggest a diathesis of superficial fibromatosis — same fibroblast biology

— Family history clusters

— Systemic sclerosis: skin thickening, Raynaud, esophageal dysmotility — distinct multisystem disease

— IgG4-related disease: rare, can cause fibroinflammatory plaques in various organs; not classically penile

— Asymmetric corporal sizes (mild, normal variant)

— Hourglass appearance from a constrictive ring during intercourse (foreign body, tight prosthesis sleeve)

— Body dysmorphic disorder — perception of curvature without objective findings; consider especially in young men with normal exam and normal photographs

— Beta-blockers historically implicated but evidence weak

— No medication confirmed as causative

— Radiation for prostate or rectal cancer can cause vascular and tunical fibrosis with secondary curvature

— Distinguished by clear radiation history and diffuse rather than focal plaque

— Radical prostatectomy (recognized risk factor)

— Penile or perineal surgery with tunical injury

Erectile dysfunction without curvature:

Systemic fibrotic disorders associated with Peyronie:

Connective tissue / autoimmune mimickers:

Functional causes of "curvature" complaints:

Drug-induced fibrosis (controversial):

Pelvic radiation:

Iatrogenic post-surgical:

Key distinction: A patient with palmar nodules, ring finger contracture, and a dorsal penile plaque has the classic Peyronie–Dupuytren association — both are superficial fibromatoses sharing TGF-β–driven fibroblast biology. Stem-level recognition is high-yield.

Board pearl: A man complaining of severe curvature whose erect photographs and exam show a straight, normal penis likely has body dysmorphic disorder — recognize this and refer for mental health evaluation rather than surgical intervention; operating on these patients leads to dissatisfaction and litigation.

Secondary Prevention / Discharge Medications / Long-Term Plan

— Smoking cessation — endothelial dysfunction worsens both Peyronie progression and ED

— Glycemic control if diabetic (target individualized A1c, often <7%)

— Blood pressure control per ACC/AHA targets (<130/80 for most)

— Lipid optimization with statin per ASCVD risk

— Regular aerobic exercise — improves endothelial function and erectile function

— Weight management, Mediterranean diet

— Limit alcohol, avoid recreational drugs

— Avoid forceful or aberrant intercourse positions that cause penile bending

— Counsel on lubrication, partner positioning to reduce buckling injuries

— Daily low-dose tadalafil 2.5–5 mg for combined ED management and possible antifibrotic benefit

— Continue penile traction therapy for several months post-CCH or post-surgery to consolidate gains and maintain length

— Address testosterone deficiency if confirmed — improves response to PDE5i

— Continue vitamin E only if patient strongly prefers (placebo-level evidence, harmless)

— Abstain from sexual activity and masturbation per protocol (typically 4 weeks post-CCH; 6 weeks post-surgery)

— Wound care, ice, scrotal/penile support

— Recognize signs of corporal rupture or infection

— Resume PDE5i per urology guidance

— Early PDE5i, vacuum erection device, possibly traction therapy

— Reduces risk of subsequent Peyronie and ED

— Annual ASCVD risk recalculation

— USPSTF-aligned cancer screening (colorectal, lung if smoker, prostate per shared decision-making)

— Vaccinations: influenza, COVID-19, pneumococcal per age, Tdap, shingles (RZV) ≥50, RSV ≥75

There is no proven primary prevention for Peyronie disease — it's a sporadic acquired fibrosis. Secondary prevention focuses on disease progression, ED, cardiovascular risk, and recurrence after treatment.

Lifestyle and risk-factor modification (every Peyronie patient):

Sexual practice counseling:

Long-term medical regimen after diagnosis/treatment:

Post-surgical / post-CCH discharge instructions:

Post-prostatectomy penile rehabilitation (if applicable):

Cardiovascular preventive care (Step 3 family medicine integration):

Step 3 management: A man newly diagnosed with Peyronie disease should leave the visit with: (1) urology referral, (2) home erect-state photographs requested, (3) labs ordered (A1c, lipids, morning testosterone), (4) tadalafil 5 mg daily if ED, (5) smoking cessation/lifestyle counseling, (6) PHQ-9 screen, (7) follow-up in 4–6 weeks.

Board pearl: ED is a sentinel marker of subclinical CV disease — every man with Peyronie + ED needs full ASCVD risk assessment and intensive secondary prevention.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Initial diagnosis visit: confirm clinical findings, labs, referral, baseline PROMs

— 4–6 weeks: review lab results, reinforce lifestyle, check on urology referral, address depression/anxiety, optimize ED therapy

— Every 3 months during active phase: track pain, curvature progression (photographs), PDQ score, IIEF-5

— Every 6–12 months in stable phase: maintain CV risk reduction, screen depression, monitor sexual function

— Photographs of erect penis every 3 months during active phase — best objective tracking

— PDQ every 3–6 months to track bother and psychological impact

— IIEF-5/SHIM to track erectile function trajectory

— Stretched penile length in clinic at each urology visit

— A1c, lipid panel, BP annually or per ASCVD/DM cadence

— Testosterone if symptoms recur or initially low

— Curvature assessment 6 weeks after final cycle

— Watch for delayed corporal rupture signs

— Repeat duplex if planning further intervention

— 2 weeks: wound check

— 6 weeks: resume sexual activity

— 3 and 6 months: function assessment, photographs, PROMs

— 12 months: long-term outcome documentation

— Penile traction therapy for 30–90 min/day for 3–6 months post-treatment — supported by evidence for length preservation and modest curvature reduction

— Pelvic floor physical therapy can improve ED and ejaculatory control in selected patients

— PDE5i daily dosing as functional rehabilitation, especially post-prostatectomy

— Set realistic expectations: no treatment perfectly restores a straight, full-length penis; goal is functional intercourse and reduced bother

— Address partner involvement when appropriate

— Refer to sex therapy or couples counseling for relationship dysfunction

— Treat depression aggressively — start SSRI cautiously (some worsen sexual function; consider bupropion or mirtazapine if sexual side effects are a concern)

— Encourage support groups and reputable patient resources (Urology Care Foundation)

Follow-up cadence in family medicine / primary care:

Monitoring parameters:

Post-CCH monitoring:

Post-surgical follow-up (typical urology cadence):

Rehabilitation:

Counseling priorities:

Step 3 management: Follow-up is outpatient and longitudinal — family physician coordinates CV risk reduction, depression screening, and PROM tracking while urology drives procedural decisions. Document phase, curvature degree, and treatment goals at each visit.

Board pearl: Bupropion is the antidepressant of choice when treating depression in a man with sexual dysfunction — it is the only commonly used antidepressant without sexual side effects and may even improve libido.

Ethical, Legal, and Patient Safety Considerations

— Patients must understand that no Peyronie treatment fully restores a "normal" penis

— For plication: explicit discussion of penile shortening (1–1.5 cm or more) is mandatory; failure to document this is a frequent malpractice claim

— For grafting: explicit discussion of 15–25% risk of postoperative ED

— For prosthesis: explicit discussion that natural erections are permanently eliminated, infection risk, mechanical failure risk

— Provide written information; document discussion in detail

— Use teach-back to confirm understanding

— Multiple acceptable treatment paths exist — match to patient values (length preservation vs. curvature correction vs. avoiding ED risk)

— Involve partner with patient's permission when appropriate

— Recognize the patient with normal exam/photographs who insists on surgery — operating on BDD patients yields dissatisfaction and harm

— Refer for psychiatric evaluation; defer surgery

— Ethical principle: nonmaleficence

— Adult competent patients have full autonomy to choose or decline treatment

— Cognitive impairment in elderly patients with prosthesis consideration: assess capacity formally; surrogate involvement if needed

— Sexual health is highly sensitive — ensure private space, never disclose to family members without consent

— Telehealth visits: confirm private location at patient's end

— EMR portal messages: patients may share with family — confirm preferred communication

— PDE5i + nitrates = hypotensive crisis; absolute contraindication — always screen

— PDE5i + alpha-blockers: use caution, separate dosing, start low

— CCH injection: ensure no anticoagulation that increases hematoma/rupture risk; counsel on activity restriction

— Document post-injection precautions in writing — failure to abstain from intercourse is the most common cause of corporal rupture and a clear safety event

— At the family medicine → urology handoff, share: phase, photographs, comorbidity workup, depression screen, current meds, CV risk

— Post-procedure, urology should communicate: procedure performed, restrictions, when to resume PDE5i, follow-up plan — close the loop

— Missed communication during transitions is a leading cause of postoperative complications and patient dissatisfaction

Informed consent — surgical Peyronie cases (high-yield Step 3 ethics):

Shared decision-making:

Body dysmorphic disorder (BDD):

Capacity and autonomy:

Confidentiality:

Patient safety — medication and procedure:

Transitions of care (Step 3 flavor):

Mandatory reporting: Not applicable to Peyronie specifically; however, if a sexual assault history emerges during intimate exam, follow state-mandated reporting and connect patient with advocacy services.

Board pearl: The single most common malpractice claim in Peyronie surgery is inadequate documentation of expected penile shortening before plication — protect yourself and your patient by detailed written consent and chart documentation.

Step 3 management: Always document phase, expected outcomes, alternatives discussed, risks, and patient's stated goals — this is both ethical practice and legal protection.

High-Yield Associations and Rapid-Fire Clinical Facts

Peyronie ↔ Dupuytren contracture (15–20%) — most testable association

Peyronie ↔ Ledderhose disease (plantar fascia fibrosis)

Peyronie ↔ post-radical prostatectomy (15–16% within 1–2 years)

Peyronie ↔ diabetes, HTN, dyslipidemia, smoking — vascular/fibrotic diathesis

TGF-β is the central cytokine in plaque pathogenesis

Plaque location: dorsal midline most common

Curvature direction: dorsal most common

Active phase: ≤12 months, pain present, evolving deformity

Stable phase: >12 months, ≥3 months unchanged, no pain

Collagenase Clostridium histolyticum (Xiaflex) = only FDA-approved drug; for stable phase, 30–90° curvature, no ventral plaques, no severe calcification

Vitamin E = classic "wrong answer" — no proven efficacy, but harmless

Intralesional steroids = should NOT be offered

Shockwave therapy = may reduce pain, no curvature benefit

Topical verapamil = should NOT be offered

Plication = shortens; for <60° curvature, good erections

Grafting = preserves length; for >60° or complex curve; risk of ED

Penile prosthesis = for Peyronie + significant ED

Corporal rupture after CCH = 0.5%, surgical emergency

Penile fracture = audible pop, eggplant deformity, urgent surgical repair within 24 hours

Congenital curvature = lifelong, ventral, no plaque, no pain

ED + Peyronie in middle-aged man = full CV risk workup (A1c, lipids, BP, ASCVD score)

PDE5i + nitrates = absolutely contraindicated

PDQ = validated PROM for Peyronie bother

IIEF-5/SHIM = validated ED screening tool

Penile traction therapy = adjunct in active phase, post-CCH, post-surgery

Daily tadalafil 2.5–5 mg = treats ED, possible antifibrotic effect

Spontaneous improvement in only ~13%; ~40% progress without treatment; rest stabilize

Photographs of erect penis = AUA-endorsed objective measure

Penile duplex ultrasound with intracavernosal injection = single most informative imaging test

Bupropion = antidepressant of choice with comorbid sexual dysfunction

Mondor disease of penis = superficial thrombosed vein, self-limited, NOT Peyronie

Hypogonadism prevalence in Peyronie ~25%

Depression prevalence in Peyronie ~48%

Key distinction: "Acute, painful, evolving" = active phase → medical therapy; "stable, painless, fixed" = chronic phase → surgical candidate. Phase drives every management decision.

Board pearl: If a stem mentions palmar nodules + ring finger flexion contracture + new penile curvature, the diagnosis is Peyronie disease with comorbid Dupuytren contracture — instant recognition.

Board Question Stem Patterns

— 58-year-old man with painful erection × 6 months, palpable dorsal penile nodule, 40° dorsal curvature. PMH: palmar nodules with early ring finger contracture.

— Next best step? → Clinical diagnosis of Peyronie disease; reassurance + photographs + urology referral + ED/CV risk workup. Recognize Dupuytren association.

— 55-year-old man with stable 50° curvature × 18 months, no pain, plaque palpable, mild ED.

— Next step? → Stable phase + 30–90° curve → intralesional collagenase (Xiaflex) candidate. Avoid: surgery prematurely (he meets criteria but injection is less invasive first), vitamin E (no evidence), steroids (harmful).

— 60-year-old man, stable disease, 70° dorsal curvature with hourglass deformity, IIEF-5 = 22 (good erections).

— Best treatment? → Plaque incision and grafting (preserves length, corrects severe curvature, erections preserved enough to justify).

— 65-year-old diabetic man, stable Peyronie, 60° curvature, severe ED unresponsive to maximal PDE5i.

— Best treatment? → Inflatable penile prosthesis with manual modeling.

— 19-year-old with lifelong ventral penile curvature noted since first erections, no plaque, no pain.

— Diagnosis? → Congenital penile curvature, not Peyronie. Plication after maturity if disabling.

— 35-year-old, audible pop during intercourse, immediate detumescence, "eggplant" swelling.

— Next step? → Urgent surgical exploration and tunical repair within 24 hours; NOT Peyronie.

— Man returns 2 days after CCH injection with sudden detumescence after intercourse (he violated abstinence), severe pain, large hematoma.

— Diagnosis? → Corporal rupture → urgent urology, MRI/surgical exploration.

— 52-year-old with new ED and Peyronie, smoker, BP 148/92, BMI 31.

— Best next step? → A1c, fasting lipids, ASCVD risk calculation, smoking cessation, BP management — treat the vascular substrate, not just the penis.

— Any Peyronie stem offering vitamin E, intralesional corticosteroid, topical verapamil, or shockwave for curvature reduction as the "best therapy" → these are AUA-flagged as not effective.

— Man with Peyronie + ED prescribed sildenafil; takes SL nitroglycerin for angina.

— Action? → Contraindicated combination — choose alternative ED therapy (vacuum device, intracavernosal injection, prosthesis) and cardiology consult.

Stem 1 — The classic association:

Stem 2 — Phase determination:

Stem 3 — Surgical selection:

Stem 4 — Prosthesis indication:

Stem 5 — Differential — congenital:

Stem 6 — Differential — penile fracture:

Stem 7 — Complication after CCH:

Stem 8 — CV risk integration:

Stem 9 — Wrong-answer recognition:

Stem 10 — Drug interaction safety:

Board pearl: When two correct-sounding answers appear (e.g., "intralesional collagenase" vs. "surgical plication"), phase + curvature degree decides: stable + 30–90° → collagenase; stable + >60° complex with good erections → grafting; stable + severe ED → prosthesis.

Step 3 management: Always sequence: history → exam → phase determination → comorbidity screen → photographs/duplex → phase-appropriate therapy.

One-Line Recap

Peyronie disease is an acquired tunica albuginea fibrosis that presents with a palpable plaque, painful erection, and penile curvature; management is phase-based — observation, ED treatment, and intralesional collagenase in the stable phase for 30–90° curves, with surgical plication, grafting, or penile prosthesis reserved for stable, disabling deformity tailored to erectile function.

— Clinical diagnosis based on history (painful erection, curvature, plaque) + exam (palpable dorsal tunical nodule)

— Confirm with penile duplex ultrasound with intracavernosal injection when curvature degree, plaque calcification, or hemodynamics are needed

— Obtain home erect-state photographs as standard objective documentation

— Screen for Dupuytren contracture, diabetes, hypogonadism, depression, and full CV risk

— Active phase (≤12 months, painful, evolving): observe, treat pain, treat ED, traction therapy, optimize CV risk; avoid surgery

— Stable phase (≥3 months unchanged, ≥12 months from onset): intralesional collagenase (Xiaflex) for 30–90° curve without ventral plaque or heavy calcification; surgery for disabling deformity

— Plication for curve <60° with good erections — shortens penis 1–1.5 cm

— Plaque incision/grafting for curve >60° or complex/hourglass with good erections — preserves length, 15–25% ED risk

— Inflatable penile prosthesis for Peyronie + severe ED unresponsive to PDE5i — single combined operation, highest satisfaction in this subgroup

— Every Peyronie patient needs ASCVD risk reduction, depression screening (PHQ-9), and realistic expectation counseling

— PDE5i + nitrates = absolutely contraindicated

— Avoid vitamin E, intralesional steroids, topical verapamil, shockwave for curvature — not evidence-supported

— Document expected penile shortening before plication — leading malpractice pitfall

High-yield bullet recap 1 — Diagnosis:

High-yield bullet recap 2 — Phase-based therapy:

High-yield bullet recap 3 — Surgical selection:

High-yield bullet recap 4 — Integration and safety:

Board pearl: Phase + curvature degree + erectile function = the three-variable decision matrix that drives every Peyronie management question on Step 3.